{"id":48750,"date":"2025-11-21T21:34:08","date_gmt":"2025-11-21T13:34:08","guid":{"rendered":"https:\/\/flcube.com\/?p=48750"},"modified":"2025-11-21T21:34:09","modified_gmt":"2025-11-21T13:34:09","slug":"pfizers-hympavzi-wins-china-approval-as-first-weekly-non%e2%80%91factor-hemophilia-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48750","title":{"rendered":"Pfizer&#8217;s Hympavzi Wins China Approval as First Weekly Non\u2011Factor Hemophilia Therapy"},"content":{"rendered":"\n<p><strong>Pfizer Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE: PFE<\/a>) announced that <strong>Hympavzi (marstacimab)<\/strong>, the world\u2019s first <strong>non\u2011factor hemophilia therapy<\/strong> requiring only a <strong>once\u2011weekly fixed\u2011dose subcutaneous injection<\/strong>, has received marketing approval from China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> for routine prophylaxis in patients aged <strong>\u226512 years and weighing \u226535\u202fkg<\/strong> with severe Hemophilia A or B without inhibitors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Hympavzi (marstacimab)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Pfizer Inc. (NYSE: PFE)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Marketing authorization (first\u2011in\u2011class)<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Severe Hemophilia A (FVIII\u202f&lt;\u202f1%) or Hemophilia B (FIX\u202f&lt;\u202f1%) without inhibitors<\/td><\/tr><tr><td><strong>Age\/Weight<\/strong><\/td><td>\u226512 years, \u226535\u202fkg<\/td><\/tr><tr><td><strong>Key Innovation<\/strong><\/td><td>Once\u2011weekly subcutaneous injection vs. IV factor replacement<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Launch expected Q1\u202f2026; reimbursement negotiations underway<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>Non\u2011factor therapy<\/strong> targeting <strong>Tissue Factor Pathway Inhibitor (TFPI)<\/strong> to rebalance coagulation, bypassing need for factor VIII or IX replacement<\/li>\n\n\n\n<li><strong>Administration:<\/strong> <strong>Fixed\u2011dose subcutaneous injection<\/strong> once weekly vs. traditional IV factor infusion (multiple times weekly)<\/li>\n\n\n\n<li><strong>Dual Indication:<\/strong> Single product treats <strong>both Hemophilia A and B<\/strong>, simplifying inventory and prescribing<\/li>\n\n\n\n<li><strong>Clinical Burden Reduction:<\/strong> Subcutaneous route eliminates need for venous access and reduces infusion time from hours to minutes<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-summary\">Clinical Evidence Summary<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Basis:<\/strong> Phase\u202fIII <strong>BASIS study<\/strong> demonstrated <strong>91% reduction<\/strong> in treated bleeds vs. on\u2011demand factor therapy; <strong>non\u2011inferior<\/strong> to prophylactic factor in Hemophilia A and B patients without inhibitors<\/li>\n\n\n\n<li><strong>Safety:<\/strong> Consistent with mechanism; no unexpected thrombotic events; injection\u2011site reactions in <strong>15%<\/strong> of patients (mild\u2011moderate)<\/li>\n\n\n\n<li><strong>Patient Preference:<\/strong> <strong>85%<\/strong> of trial participants preferred subcutaneous weekly dosing over IV factor regimens<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>China Hemophilia Patients (Severe A\/B)<\/strong><\/td><td>~30,000 patients (A: 22,000; B: 8,000)<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>Factor replacement (IV) 2\u20113\u00d7 weekly; costs \u00a5200,000\u2011400,000\/year<\/td><\/tr><tr><td><strong>Hympavzi Pricing<\/strong><\/td><td>Estimated \u00a5250,000\u2011300,000\/year (aligned with factor prophylaxis)<\/td><\/tr><tr><td><strong>Market Penetration Target<\/strong><\/td><td>20\u201130% of eligible patients by 2028<\/td><\/tr><tr><td><strong>Peak Sales Forecast (China)<\/strong><\/td><td><strong>\u00a51.5\u20112.0\u202fbillion<\/strong> (US$200\u2011270\u202fmillion) by 2029<\/td><\/tr><tr><td><strong>Global Context<\/strong><\/td><td>Approved in US (FDA, Oct\u202f2024) and EU (Feb\u202f2025); China approval completes major market access<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reimbursement Path:<\/strong> Expected to be included in <strong>China National Reimbursement Drug List (NRDL)<\/strong> by 2027 based on novel mechanism and patient convenience; Pfizer is prepared for price negotiation.<\/li>\n\n\n\n<li><strong>Competitive Moat:<\/strong> <strong>First and only<\/strong> weekly subcutaneous non\u2011factor therapy; no biosimilar pathway; patent protection through <strong>2038<\/strong> in China.<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Strengthens Pfizer\u2019s rare disease portfolio in China, complementing <strong>BeneFIX<\/strong> (FIX) and <strong>Xyntha<\/strong> (FVIII) while addressing the <strong>15\u201120%<\/strong> of patients who develop inhibitors.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Hympavzi\u2019s commercial launch, reimbursement negotiations, and market penetration in China. Actual results may differ materially due to risks including pricing negotiations, competitive responses, and patient adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer Inc. (NYSE: PFE) announced that Hympavzi (marstacimab), the world\u2019s first non\u2011factor hemophilia therapy requiring&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48751,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[863,309,15,24],"class_list":["post-48750","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-nyse-pfe","tag-pfizer","tag-product-approvals","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer&#039;s Hympavzi Wins China Approval as First Weekly Non\u2011Factor Hemophilia Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Pfizer Inc. (NYSE: PFE) announced that Hympavzi (marstacimab), the world\u2019s first non\u2011factor hemophilia therapy requiring only a once\u2011weekly fixed\u2011dose subcutaneous injection, has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for routine prophylaxis in patients aged \u226512 years and weighing \u226535\u202fkg with severe Hemophilia A or B without inhibitors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48750\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer&#039;s Hympavzi Wins China Approval as First Weekly Non\u2011Factor Hemophilia Therapy\" \/>\n<meta property=\"og:description\" content=\"Pfizer Inc. (NYSE: PFE) announced that Hympavzi (marstacimab), the world\u2019s first non\u2011factor hemophilia therapy requiring only a once\u2011weekly fixed\u2011dose subcutaneous injection, has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for routine prophylaxis in patients aged \u226512 years and weighing \u226535\u202fkg with severe Hemophilia A or B without inhibitors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48750\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-21T13:34:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-21T13:34:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2101.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48750#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48750\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer&#8217;s Hympavzi Wins China Approval as First Weekly Non\u2011Factor Hemophilia Therapy\",\"datePublished\":\"2025-11-21T13:34:08+00:00\",\"dateModified\":\"2025-11-21T13:34:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48750\"},\"wordCount\":428,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48750#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2101.webp\",\"keywords\":[\"NYSE: PFE\",\"Pfizer\",\"Product approvals\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48750#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48750\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48750\",\"name\":\"Pfizer's Hympavzi Wins China Approval as First Weekly Non\u2011Factor Hemophilia Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48750#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48750#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2101.webp\",\"datePublished\":\"2025-11-21T13:34:08+00:00\",\"dateModified\":\"2025-11-21T13:34:09+00:00\",\"description\":\"Pfizer Inc. (NYSE: PFE) announced that Hympavzi (marstacimab), the world\u2019s first non\u2011factor hemophilia therapy requiring only a once\u2011weekly fixed\u2011dose subcutaneous injection, has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for routine prophylaxis in patients aged \u226512 years and weighing \u226535\u202fkg with severe Hemophilia A or B without inhibitors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48750#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48750\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48750#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2101.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2101.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pfizer's Hympavzi Wins China Approval as First Weekly Non\u2011Factor Hemophilia Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48750#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer&#8217;s Hympavzi Wins China Approval as First Weekly Non\u2011Factor Hemophilia Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer's Hympavzi Wins China Approval as First Weekly Non\u2011Factor Hemophilia Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Pfizer Inc. (NYSE: PFE) announced that Hympavzi (marstacimab), the world\u2019s first non\u2011factor hemophilia therapy requiring only a once\u2011weekly fixed\u2011dose subcutaneous injection, has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for routine prophylaxis in patients aged \u226512 years and weighing \u226535\u202fkg with severe Hemophilia A or B without inhibitors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48750","og_locale":"en_US","og_type":"article","og_title":"Pfizer's Hympavzi Wins China Approval as First Weekly Non\u2011Factor Hemophilia Therapy","og_description":"Pfizer Inc. (NYSE: PFE) announced that Hympavzi (marstacimab), the world\u2019s first non\u2011factor hemophilia therapy requiring only a once\u2011weekly fixed\u2011dose subcutaneous injection, has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for routine prophylaxis in patients aged \u226512 years and weighing \u226535\u202fkg with severe Hemophilia A or B without inhibitors.","og_url":"https:\/\/flcube.com\/?p=48750","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-21T13:34:08+00:00","article_modified_time":"2025-11-21T13:34:09+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2101.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48750#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48750"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer&#8217;s Hympavzi Wins China Approval as First Weekly Non\u2011Factor Hemophilia Therapy","datePublished":"2025-11-21T13:34:08+00:00","dateModified":"2025-11-21T13:34:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48750"},"wordCount":428,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48750#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2101.webp","keywords":["NYSE: PFE","Pfizer","Product approvals","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48750#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48750","url":"https:\/\/flcube.com\/?p=48750","name":"Pfizer's Hympavzi Wins China Approval as First Weekly Non\u2011Factor Hemophilia Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48750#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48750#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2101.webp","datePublished":"2025-11-21T13:34:08+00:00","dateModified":"2025-11-21T13:34:09+00:00","description":"Pfizer Inc. (NYSE: PFE) announced that Hympavzi (marstacimab), the world\u2019s first non\u2011factor hemophilia therapy requiring only a once\u2011weekly fixed\u2011dose subcutaneous injection, has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for routine prophylaxis in patients aged \u226512 years and weighing \u226535\u202fkg with severe Hemophilia A or B without inhibitors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48750#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48750"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48750#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2101.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2101.webp","width":1080,"height":608,"caption":"Pfizer's Hympavzi Wins China Approval as First Weekly Non\u2011Factor Hemophilia Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48750#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer&#8217;s Hympavzi Wins China Approval as First Weekly Non\u2011Factor Hemophilia Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2101.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48750","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48750"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48750\/revisions"}],"predecessor-version":[{"id":48752,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48750\/revisions\/48752"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48751"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48750"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48750"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}